GAITHERSBURG, Md., June 19 /PRNewswire/ -- MedImmune, Inc. today announced that its founder, Wayne T. Hockmeyer, Ph.D., is retiring as president of MedImmune Ventures, Inc. Dr. Hockmeyer also stepped down as the company's chairman upon AstraZeneca's completion of its tender offer to acquire all outstanding shares of MedImmune common stock.
Dr. Hockmeyer commented: "I am honored to have been a part of building one of the most successful biotechnology companies in the world. The last 19 years at MedImmune have been exciting, professionally stimulating and remarkably productive. I believe the company, now as a part of AstraZeneca, will continue to be successful in developing new and promising therapies that improve healthcare. I also expect MedImmune to continue to grow as one of the premier biotech companies, adding new jobs, playing an important leadership role in the scientific community, and continuing its involvement as a dedicated corporate citizen."
About MedImmune, Inc.
MedImmune strives to provide better medicines to patients, new medical options for physicians, and rewarding careers to employees. Dedicated to advancing science and medicine to help people live better lives, the company is focused on the areas of infectious diseases, cancer and inflammatory diseases. With more than 2,500 employees worldwide, MedImmune is headquartered in Maryland. For more information, visit the company's website at http://www.medimmune.com .
CONTACT: Kate Barrett for MedImmune, Inc., +1-301-398-4320